Balovaptan + Placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Autism Spectrum Disorder
Conditions
Autism Spectrum Disorder
Trial Timeline
Aug 8, 2018 → Jul 1, 2020
NCT ID
NCT03504917About Balovaptan + Placebo
Balovaptan + Placebo is a phase 3 stage product being developed by Roche for Autism Spectrum Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT03504917. Target conditions include Autism Spectrum Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05401565 | Phase 2 | Completed |
| NCT05399550 | Phase 2 | Withdrawn |
| NCT03504917 | Phase 3 | Terminated |
Competing Products
20 competing products in Autism Spectrum Disorder